Compare Shimadzu Corp. with Similar Stocks
Dashboard
1
With ROE of 10.87%, it has a very attractive valuation with a 2.10 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 23.16%, its profits have risen by 6.9% ; the PEG ratio of the company is 2.8
- At the current price, the company has a high dividend yield of 0
2
Majority shareholders : FIIs
Stock DNA
Pharmaceuticals & Biotechnology
JPY 1,201,453 Million (Large Cap)
19.00
NA
0.00%
-0.29
10.78%
2.13
Revenue and Profits:
Net Sales:
130,596 Million
(Quarterly Results - Jun 2026)
Net Profit:
13,332 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.14%
0%
6.14%
6 Months
-3.41%
0%
-3.41%
1 Year
23.8%
0%
23.8%
2 Years
-4.72%
0%
-4.72%
3 Years
-3.96%
0%
-3.96%
4 Years
-13.14%
0%
-13.14%
5 Years
-13.05%
0%
-13.05%
Shimadzu Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.68%
EBIT Growth (5y)
9.96%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
1.05
Tax Ratio
25.73%
Dividend Payout Ratio
32.95%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
22.70%
ROE (avg)
11.59%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
2.10
EV to EBIT
13.01
EV to EBITDA
10.16
EV to Capital Employed
2.49
EV to Sales
1.76
PEG Ratio
2.80
Dividend Yield
NA
ROCE (Latest)
19.17%
ROE (Latest)
10.87%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
130,596.00
118,370.00
10.33%
Operating Profit (PBDIT) excl Other Income
19,743.00
17,412.00
13.39%
Interest
59.00
65.00
-9.23%
Exceptional Items
25.00
26.00
-3.85%
Consolidate Net Profit
13,332.00
7,921.00
68.31%
Operating Profit Margin (Excl OI)
109.20%
102.90%
0.63%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 10.33% vs 1.22% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 68.31% vs -20.69% in Jun 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
560,728.00
539,047.00
4.02%
Operating Profit (PBDIT) excl Other Income
94,955.00
92,402.00
2.76%
Interest
289.00
278.00
3.96%
Exceptional Items
-544.00
-1,312.00
58.54%
Consolidate Net Profit
60,498.00
53,774.00
12.50%
Operating Profit Margin (Excl OI)
131.40%
133.10%
-0.17%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 4.02% vs 5.30% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 12.50% vs -5.72% in Mar 2025
About Shimadzu Corp. 
Shimadzu Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






